Article Sidebar
Main Article Content
Functional Role of miR-499a-5p in the Development of Gastric Cancer
Main Article Content
Abstract
Background/Aims: Gastric cancer (GC) is a highly prone malignant tumor, which has attracted wide attention. This study investigated the expression and clinical value of miR-499a-5p in GC.
Materials and Methods: A total of 105 patients with GC were included in this study. Simultaneously, 55 patients with benign stomach disorders and 45 healthy subjects were enrolled as controls. Real-time quantitative polymerase chain reaction was used to determine the expression of miR-499a-5p. The receiver operating characteristic curve was used to assess the diagnostic value of miR-499a-5p in GC. Kaplan–Meier and logistic analyses were used to evaluate the association between miR-499a-5p and GC prognosis.
Results: The levels of miR-499a-5p are markedly downregulated in GC and have a high diagnostic value. miR-499a-5p is closely linked to pathological features of GC. Overexpression of miR-499a-5p inhibits GC cell growth, migration, and invasion. Furthermore, miR-499a-5p is also related to GC and 5-year survival, and is a risk factor for GC death.
Conclusion: The levels of miR-499a-5p were markedly downregulated in GC and related to GC pathological features. It has the potential to become a biomarker for the diagnosis of GC.
Cite this article as: Lu C, Guo C, Wu C, Zhang L, Liu X, Guo S. Functional role of miR-499a-5p in the development of gastric cancer. Turk J Gastroenterol. 2025;36(1):45-52.
Article Details
References
1. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. [CrossRef]
2. Yang L. Incidence and mortality of gastric cancer in China. World J Gastroenterol. 2006;12(1):17-20. [CrossRef]
3. Gao K, Wu J. National trend of gastric cancer mortality in China (2003-2015): a population-based study. Cancer Commun (Lond). 2019;39(1):24. [CrossRef]
4. Kono Y, Kanzaki H, Iwamuro M, Kawano S, Kawahara Y, Okada H. Reality of gastric cancer in young patients: the importance and difficulty of the early diagnosis, prevention and treatment. Acta Med Okayama. 2020;74(6):461-466. [CrossRef]
5. Irmak-Yazicioglu MB. Mechanisms of microRNA deregulation and microRNA targets in gastric cancer. Oncol Res Treat. 2016;39(3):136-139. [CrossRef]
6. Lee YS, Dutta A. MicroRNAs in cancer. Annu Rev Pathol. 2009;4:199-227. [CrossRef]
7. Tian W, Pang X, Luan F. Diagnosis value of miR-181, miR-652, and CA72-4 for gastric cancer. J Clin Lab Anal. 2022;36(6):e24411. [CrossRef]
8. Arias Sosa LA, Cuspoca Orduz AF, Bernal Gómez BM. Deregulation of microRNAs in gastric cancer: up regulation by miR-21 and miR-106. Rev Gastroenterol Peru. 2017;37(1):65-70.
9. Ye J, Xu J, Li Y, et al. DDAH1 mediates gastric cancer cell invasion and metastasis via Wnt/β-catenin signaling pathway. Mol Oncol. 2017;11(9):1208-1224. [CrossRef]
10. Zhang G, Gao Z, Guo X, et al. CAP2 promotes gastric cancer metastasis by mediating the interaction between tumor cells and tumor-associated macrophages. J Clin Invest. 2023;133(21). [CrossRef]
11. Shi H, Yang X, Zhen Y, Huo S, Xiao R, Xu Z. MicroRNA499 rs3746444 A/G polymorphism functions as a biomarker to predict recurrence following endoscopic submucosal dissection in primary early gastric cancer. Mol Med Rep. 2017;15(5):3245-3251. [CrossRef]
12. Wang Y, Jiang R, Zhao H, Li F, Li Y, Zhu M. TTN-AS1 delivered by gastric cancer cell-derived exosome induces gastric cancer progression through in vivo and in vitro studies. Cell Biol Toxicol. 2023;39(2):557-571. [CrossRef]
13. Fu XY, Mao XL, Chen YH, et al. The feasibility of applying artificial intelligence to gastrointestinal endoscopy to improve the detection rate of early gastric cancer screening. Front Med (Lausanne). 2022;9:886853. [CrossRef]
14. Necula L, Matei L, Dragu D, et al. Recent advances in gastric cancer early diagnosis. World J Gastroenterol. 2019;25(17):2029-2044. [CrossRef]
15. He F, He RX. Systematic nursing interventions in gastric cancer: a randomized controlled study. World J Clin Cases. 2022;10(6):1843-1851. [CrossRef]
16. Mizukami T, Piao Y. Role of nutritional care and general guidance for patients with advanced or metastatic gastric cancer. Future Oncol. 2021;17(23):3101-3109. [CrossRef]
17. Giraldo NA, Peske JD, Sautès-Fridman C, Fridman WH. Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology. Virchows Arch. 2019;474(4):463-474. [CrossRef]
18. Virgilio E, Giarnieri E, Montagnini M, et al. Detection of cancer cells and tumor markers in gastric lavage of patients with gastric cancer: do these findings have a clinicopathological significance and oncological implication? Med Hypotheses. 2016;94:1-3. [CrossRef]
19. Fadaei M, Kohansal M, Akbarpour O, Sami M, Ghanbariasad A. Network and functional analyses of differentially expressed genes in gastric cancer provide new biomarkers associated with disease pathogenesis. J Egypt Natl Cancer Inst. 2023;35(1):8. [CrossRef]
20. Ghafouri-Fard S, Vafaee R, Shoorei H, Taheri M. MicroRNAs in gastric cancer: biomarkers and therapeutic targets. Gene. 2020;757:144937. [CrossRef]
21. Shin VY, Chu KM. MiRNA as potential biomarkers and therapeutic targets for gastric cancer. World J Gastroenterol. 2014;20(30):10432-10439. [CrossRef]
22. Bai SY, Ji R, Wei H, et al. Serum miR-551b-3p is a potential diagnostic biomarker for gastric cancer. Turk J Gastroenterol. 2019;30(5):415-419. [CrossRef]
23. Liu S, Suo J, Wang C, et al. Prognostic significance of low miR-144 expression in gastric cancer. Cancer Biomark. 2017;20(4):547-552. [CrossRef]
24. Ma H, Wang P, Li Y, Yang Y, Zhan S, Gao Y. Decreased expression of serum miR-647 is associated with poor prognosis in gastric cancer. Int J Clin Exp Pathol. 2019;12(7):2552-2558.
25. Chen X, Liu XS, Liu HY, Lu YY, Li Y. Reduced expression of serum miR-204 predicts poor prognosis of gastric cancer. Genet Mol Res. 2016;15(2). [CrossRef]
26. Feng R, Beeharry MK, Lu S, et al. Down-regulated serum miR-126 is associated with aggressive progression and poor prognosis of gastric cancer. Cancer Biomark. 2018;22(1):119-126. [CrossRef]
27. Chen Y, Sun F, Zhang L, Zhou J, Hou J. miR-499a inhibits the proliferation and apoptosis of prostate cancer via targeting UBE2V2. World J Surg Oncol. 2021;19(1):250. [CrossRef]
28. Wang BQ, Yang B, Yang HC, et al. MicroRNA-499a decelerates glioma cell proliferation while accelerating apoptosis through the suppression of Notch1 and the MAPK signaling pathway. Brain Res Bull. 2018;142:96-106. [CrossRef]
29. Li X, Tibenda JJ, Nan Y, et al. MiR-204-3p overexpression inhibits gastric carcinoma cell proliferation by inhibiting the MAPK pathway and RIP1/MLK1 necroptosis pathway to promote apoptosis. World J Gastroenterol. 2023;29(29):4542-4556. [CrossRef]
30. Gao Y, Wang Y, Wang X, et al. miR-335-5p suppresses gastric cancer progression by targeting MAPK10. Cancer Cell Int. 2021;21(1):71. [CrossRef]